Apple stock is rising today: here's why
Source: invezz.com

Apple shares gained 2% after Counterpoint Research projected sales of 6 million units for the upcoming iPhone Duo, Apple's first foldable smartphone. Pre-orders begin Oct. 16 ahead of an Oct. 23 launch, while UBS reported that iPhone 18 Pro and Pro Max wait times remain broadly unchanged, signaling stable demand for premium models.
Analysis
The relevant earnings lever is mix rather than unit volume. Even assuming a premium $1,800-$2,200 price point, initial foldable volume would represent a low-single-digit percentage of annual iPhone shipments and likely less than 3% of total company revenue; it is insufficient alone to change consensus FY estimates. The investable question is whether the device expands Apple’s premium handset ASP and upgrade cohort rather than cannibalizes the highest-margin Pro/Pro Max mix.
Unchanged Pro availability signals that the premium demand backdrop has not visibly tightened, limiting the evidence for a broad replacement-cycle acceleration. Near term, AAPL’s move is therefore more vulnerable to launch-week demand data than supported by a material earnings revision. Component economics also matter: early-generation foldable displays, hinges, and battery density can dilute hardware gross margin unless Apple’s pricing premium exceeds incremental bill-of-materials costs; Samsung Display is a likely second-order beneficiary if it is the primary flexible-OLED supplier.
Over 6-18 months, Apple’s strategic upside is defensive: a credible foldable form factor narrows Samsung’s differentiation and can raise switching costs within the iOS installed base. The contrarian view is that the market may overvalue novelty while underweighting durability, crease, repair-cost, and app-optimization concerns—issues that have constrained foldable adoption across Android. A weak preorder conversion rate or evidence of Pro cannibalization would turn a perceived ASP catalyst into a mix-and-margin headwind.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
Key Decisions for Investors
- Do not chase AAPL on the initial launch narrative; maintain only a tactical long bias into preorder data, with a 1-3 month thesis contingent on premium mix rather than headline unit demand. Add only if management/commentary supports net ASP accretion and no reduction in Pro-family demand.
- Use AAPL versus Samsung Electronics as a 6-12 month relative-value watch: long AAPL/short Samsung becomes attractive only if independent sell-through data show meaningful iOS-driven foldable share gains. Avoid initiating before pricing, bill-of-materials, and supply-chain allocation are independently verified.
- Monitor Samsung Display supply-chain disclosures and flexible-OLED capacity utilization as a second-order confirmation signal; stronger utilization without handset-price discounting would support the premiumization thesis, while elevated warranty or repair provisions would falsify it.
- Risk-manage any AAPL launch exposure with a trigger around the first post-launch demand read: reduce if preorder lead times normalize quickly, if channel discounting emerges, or if management indicates foldable sales are predominantly replacing Pro/Pro Max purchases rather than adding upgrades.
More News
- Micron beats on revenue and earnings as global memory shortage continues
- Stocks Jump on inflation Surprise, Apple's Smart-Home Push
- Trump’s AI lunch included every major tech company. Except Apple
- Huawei unveils Mate 90 phones, leans on homegrown chip design to offset US curbs
- Meta stock enjoys best month since 2022 on AI momentum
- Bloomberg Tech: OpenAI Seeks $30B as Trump Backs Safety Audits
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AlphaSense Pricing: What Public Contract Data Shows in 2026
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market